1. Home
  2. DNTH vs ETD Comparison

DNTH vs ETD Comparison

Compare DNTH & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNTH
  • ETD
  • Stock Information
  • Founded
  • DNTH 2015
  • ETD 1932
  • Country
  • DNTH United States
  • ETD United States
  • Employees
  • DNTH N/A
  • ETD N/A
  • Industry
  • DNTH Biotechnology: Pharmaceutical Preparations
  • ETD Home Furnishings
  • Sector
  • DNTH Health Care
  • ETD Consumer Discretionary
  • Exchange
  • DNTH Nasdaq
  • ETD Nasdaq
  • Market Cap
  • DNTH 657.0M
  • ETD 700.3M
  • IPO Year
  • DNTH N/A
  • ETD 1993
  • Fundamental
  • Price
  • DNTH $17.39
  • ETD $26.37
  • Analyst Decision
  • DNTH Strong Buy
  • ETD Hold
  • Analyst Count
  • DNTH 8
  • ETD 2
  • Target Price
  • DNTH $53.00
  • ETD $30.00
  • AVG Volume (30 Days)
  • DNTH 255.5K
  • ETD 438.7K
  • Earning Date
  • DNTH 05-12-2025
  • ETD 05-05-2025
  • Dividend Yield
  • DNTH N/A
  • ETD 5.97%
  • EPS Growth
  • DNTH N/A
  • ETD N/A
  • EPS
  • DNTH N/A
  • ETD 2.25
  • Revenue
  • DNTH $6,524,000.00
  • ETD $622,924,000.00
  • Revenue This Year
  • DNTH N/A
  • ETD N/A
  • Revenue Next Year
  • DNTH N/A
  • ETD $0.96
  • P/E Ratio
  • DNTH N/A
  • ETD $11.61
  • Revenue Growth
  • DNTH 102.36
  • ETD N/A
  • 52 Week Low
  • DNTH $13.37
  • ETD $24.55
  • 52 Week High
  • DNTH $32.27
  • ETD $35.62
  • Technical
  • Relative Strength Index (RSI)
  • DNTH 35.86
  • ETD 44.49
  • Support Level
  • DNTH $17.40
  • ETD $26.02
  • Resistance Level
  • DNTH $18.45
  • ETD $26.73
  • Average True Range (ATR)
  • DNTH 1.21
  • ETD 0.62
  • MACD
  • DNTH -0.22
  • ETD -0.08
  • Stochastic Oscillator
  • DNTH 10.60
  • ETD 25.23

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

About ETD Ethan Allen Interiors Inc.

Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.

Share on Social Networks: